Clinical trials: AML/MDS
Leukemia, Acute, Chronic Myelogenous Leukemia (CML)
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Patients with hematologic malignancies will receive myeloablative chemotherapy followed by stem cell rescue with bone marrow or hematopoietic peripheral blood stem cells collected by apheresis from a filgrastim- (G-CSF)-mobilized…
- Conditions
- Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
- Trial name
- NCT01050764
- Testing
- Regulatory T-cells, Conventional T-cells, Melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Everett Meyer
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
Despite improvements in outcomes after Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), the risk of relapse remains high and is the most common cause of mortality after…
- Trial name
- UPCI 13-165 (NCT02204020)
- Testing
- 5-azacytidine (5-aza) maintenance therapy after transplant
- Where
- United States
- Sponsor
- University of Pittsburgh
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02269579
- Testing
- CPX-351
- Where
- 5 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Trial name
- NCT02198482
- Testing
- Volasertib, Cytarabine, Daunorubicin
- Where
- 45 sites in Germany
- Volunteers
- 6 people
- Sponsor
- University of Ulm
Leukemia, Acute Myeloid Leukemia (AML)
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
The purpose of the trial is to study how the elderly patients who have previously undergone treatment for acute myeloid leukemia and high-rRisk myelodysplastic syndromes, respond to a combined treatment with azacitidine and…
- Conditions
- Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT01442714
- Testing
- Azacitidine, Lenalidomide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Stanford University
Leukemia, Lymphocytic, Acute, AML
Stem Cell Transplantation for Hematological Malignancies
This protocol using busulfan, cyclophosphamide and melphalan has been designed as conditioning therapy for patients receiving stem cell transplantation for acute leukemia or myelodysplastic syndrome (MDS).
- Conditions
- Leukemia, Lymphocytic, Acute, AML, MDS
- Trial name
- NCT00176839
- Testing
- Stem Cell Transplant, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
The purpose of this study is to assess the effects of CPX-351 on cardiac repolarization, assess plasma drug levels, asses serum copper levels, and assess drug levels in urine.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02238925
- Testing
- CPX-351
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Jazz Pharmaceuticals
Leukemia, Myeloid, Chronic, AML
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.
- Conditions
- Leukemia, Myeloid, Chronic, AML, MDS, Leukemia, Lymphocytic, Acute
- Trial name
- NCT00167167
- Testing
- Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
Allogeneic transplant can sometimes be an effective treatment for leukemia. In a traditional allogeneic transplant, patients receive very high doses of chemotherapy and/or radiation therapy, followed by an infusion of their…
- Trial name
- NCT02433483
- Testing
- Cytarabine, Intrathecal Triples, HPC-A
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced and Selected Solid Tumors, AML
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
This is a multi-center, open-label, dose-finding, phase Ib study to estimate the maximum tolerated dose(s) (MTD(s)) and/or recommended dose(s) for expansion (RDE(s)) for the orally administered combination of BYL719 and MEK162.
- Conditions
- Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS
- Trial name
- NCT01449058
- Testing
- BYL719, MEK162
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Array BioPharma
Acute Leukemia, Myelodysplastic Syndromes
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
This study will use droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma mutant allele frequency (MAF) in MDS and AML patients before, during and after chemotherapy treatment.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, AML, MDS
- Trial name
- iCare3 (NCT03138395)
- Testing
- droplet digital PCR
- Sponsor
- University of Florida
Anemia, Leukemia
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
This is a single-center, single arm, open-label study of oral lenalidomide monotherapy administered to red blood cell (RBC) transfusion dependent adult subjects with Diamond-Blackfan Anemia (DBA).
- Conditions
- Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT01034592
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jason Robert Gotlib
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02259348
- Testing
- Cyclophosphamide, Fludarabine, G-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL)
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Background: Most patients with acute lymphoblastic leukemia (ALL) and many patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and non-Hodgkin's lymphoma (NHL) have a protein called Wilm's Tumor 1…
- Conditions
- Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL), Leukemia, Chronic Myelogenous (CML), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT00923910
- Testing
- WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person).
- Conditions
- For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02200380
- Testing
- CDX-301, CDX-301 and plerixafor
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
AML, ALL
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects.
- Conditions
- AML, ALL, CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL
- Trial name
- MINI HEME (NCT00636909)
- Testing
- Cyclophosphamide, fludarabine, cyclosporine
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
The purpose of this study is to determine whether CPI-613 is effective and safe in either patients with refractory or relapsed acute myeloid leukemia (AML) or patients with myelodysplastic syndrome (MDS) who have failed therapy…
- Trial name
- NCT01520805
- Testing
- CPI-613
- Where
- United States
- Sponsor
- Cornerstone Pharmaceuticals
MDS and AML Prior to Allogeneic SCT
Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial
The ALLIVE (ALLogeneic Iron inVEstigators) trial aims at quantifying the extent and dynamic change of LPI occurrence during conditioning and at identifying LPI-predictive peri-transplant parameters.
- Trial name
- ALLIVE (NCT01746147)
- Testing
- No intervention and study treatment
- Where
- 5 sites in Germany
- Volunteers
- 134 people
- Sponsor
- GWT-TUD GmbH
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
This is a prospective, open-label, nonrandomized, prospective clinical trial evaluating a fixed regimen of treosulfan, fludarabine and low-dose total body irradiation (TBI) in children with acute myeloid leukemia (AML) and…
- Trial name
- NCT01772953
- Testing
- Treosulfan
- Where
- 23 sites in United States
- Volunteers
- 40 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
CML, AML
Umbilical Cord Blood Transplant for Hematological Malignancies
This protocol will enroll subjects with advanced hematologic malignancies who do not have a suitable related or unrelated donor to undergo a Stem Cell Transplant.
- Conditions
- CML, AML, MDS, ALL
- Trial name
- UCB (NCT00891592)
- Testing
- Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania